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Abstract
Background/Aim. Diabetic nephropathy (DN) as a ma-
jor microvascular complication of diabetes mellitus (DM)
include a progressive increase in urinary albumin excretion
in association with an increase in blood pressure and to
end stage renal failure. Hypertension connected with
renin-angiotensin system (RAS) hyperactivity and corre-
sponding genotypes, angiotensinogen (AGT), angioten-
sine-converting enzyme (ACE) and angiotensin II type 1
receptor (AT1R), predispose the increasing risk of DN.
The aim of this study was to assess the distribution of
AGT, ACE and AT1R gene polymorphisms in patients
with type 1 DM according to the level of DN and patients
clinical characteristics. Methods. The study included 79
type 1 diabetic patients. Inclusion criteria were: age be-
tween 20–40, duration of diabetes > 5 years, and no other
severe diseases. Clinical characteristics were gained from
interviewing the patients. Polymorphism was detected by
polymerase chain reaction (PCR) and restriction fragment
length polymorphism using restriction enzymes Psy I (Tth
111 I) and Hae III. Results. The patients with proteinuria
compared with normo- and microalbuminuric patients,
highly differed in age, diabetes duration, blood pressure
level, hypertension, rethynopathy and urinary albumin ex-
cretion values (p < 0.001). No statistically significant dif-
ference between the groups was found for the ACE and
AT1R gene polymorphisms distribution. The presence of
TT genotype of the M235T polymorphism was signifi-
cantly higher in the group with proteinuria (p < 0.05). The
patients with hypertension raised nephropathy 5.2 times
higher (OR = 5.20, p < 0.05) while carriers of TT allel de-
veloped nephropathy 28.38 times higher (OR  = 28.389,
p < 0.01) than those with MM genotype. Conclusion. In-
creased association of hypertension and TT angiotensino-
gen gene polymorphism in patients with diabetes mellitus
with proteinuria could be a significant marker of diabetic
nephropathy.
Key words:
diabetic nephropathies; renin-angiotensin system;
diabetes mellitus, type 1; polymorphism, genetic.
Apstrakt
Uvod/Cilj. Dijabetesna nefropatija (DN) kao jedna od
najznaÿajnijih komplikacija dijabetesa melitusa (DM) uk-
ljuÿuje progresivno poveýanje urinarne ekskrecije albumi-
na koja udružena sa hipertenzijom, dovodi do terminalne
bubrežne insuficijencije. Hipertenzija i poveýana aktivnost
renin-angiotenzin sistema (RAS) uz prisustvo odreĀenih
polimorfizama gena za RAS, angiotenzinogen (AGT), an-
giotenzin-konvertujuýi enzim (ACE) i angiotenzinski re-
ceptor tipa 1 (AT1R) mogu da ukažu na poveýanu sklo-
nost ka razvoju DN. Cilj rada bio je ispitivanje distribucije
polimorfizma gena AGT, ACE i AT1R u grupi bolesnika
sa DM tipa 1 u odnosu na stepen razvoja nefropatije, defi-
nisane kliniÿke parametre i faktore rizika. Metode. Ispiti-
vanjem je bilo obuhvaýeno 79 bolesnika sa DM tipa 1, sta-
rosti 20–40 godina, trajanjem dijabetesa duže od 5 godina i
bez drugih hroniÿnih bolesti. Polimorfizam gena RAS us-
tanovljen je metodom PCR-RFLP korišýenjem restrikcio-
ne endonukleaze Psy I (Tth 111I) i Hae III. Rezultati.
Bolesnici sa proteinurijom u odnosu na normo- i mikroal-
buminuriÿne ispitanike znaÿajno su se razlikovali po godi-
nama starosti, trajanju dijabetesa, vrednosti krvnog pritis-
ka, hipertenzije, retinopatije i urinarne ekskrecije albumina
(p  <  0,001). U ispitivanim grupama, razlike u uÿestalosti
genskih polimorfizama za ACE i AT1R nisu bile statistiÿkiStrana 628 VOJNOSANITETSKI PREGLED Volumen 71, Broj 7
Iliý V, et al. Vojnosanit Pregl 2014; 71(7): 627–633.
znaÿajne. Prisustvo TT genotipa u M235T polimorfizmu
gena za AGT bio je znaÿajno viši u grupi bolesnika sa
proteinurijom (p < 0,05). Uÿestalost nefropatije bila je 5,2
puta veýa (OR = 5,20, p < 0,05) kod dijabetiÿara sa hiper-
tenzijom, dok je TT genotip ukazivao na 28.38 puta veýu
sklonost (OR = 28,389, p < 0,01) ka razvoju nefropatije u
odnosu na MM genotip. Zakljuÿak. Poveýanje uÿestalosti
hipertenzije i TT alelske forme u angiotenzinogen gen-
skom polimorfizmu kod bolesnika u terminalnom stadiju-
mu nefropatije mogu imati znaÿaj za odreĀivanje markera
procene rizika od nastanka komplikacija u dijabetesu me-
litusu tipa 1.
Kljuÿne reÿi:
dijabetiÿke nefropatije; renin-angiotenzin sistem;
dijabetes melitus, tip 1; polimorfizam, genetiÿki.
Introduction
Diabetic nephropathy (DN) is an important microvas-
cular complication of a long-standing type 1 and type 2 dia-
betes mellitus (DM) associated with considerable morbidity
and mortality. In spite of the main risk factors for the devel-
opment of DN as hypertension and poor glycemic control,
genetic susceptibility in both type 1 and type 2 DM is also of
the great importance. Other risk factors that relate to the de-
velopment of nephropathy are smoking, obesity and dyslipi-
demia 
1. Once DN is present, risk factors favorise evolution
to more advanced stage. Recent studies suggest that antihy-
pertensive drugs (angiotensine converting enzymes – ACE-
inhibitors) should be used in prevention of DN even in nor-
motensive patients.
DN is defined as increased protein excretion in urine.
Early stage is characterized by a small increase in urinary al-
bumin excretion (UAE), also called microalbuminuria or in-
cipient DN. More advanced disease is defined by the pres-
ence of macroalbuminuria or proteinuria. The latter is named
overt or “manifested” DN.
Patients with elevated level of urinary albumin excre-
tion are at high risk of cardiovascular complications and
need frequent and carefull examination for early detection of
nephropathy and cardiovascular and lipid abnormalities 
2.
Hemodynamic changes in DN, as systemic and glo-
merular hypertension, lead to the initiation and progression
of nephropathy and may be explained by alteration in the
renin-angiotensine system (RAS).
The prominent role of the component genes of the RAS
in cardiovascular regulation sugest the possibility that poly-
morphism of the genes of the RAS might be involved in the
genetic predisposition to develop DN. Among the candidate
genes of the RAS, the angiotensinogen (AGT), ACE and an-
giotensin II type 1 receptor (AT1R) genes seem to be par-
ticulary relevant to renal disease and related with predisposi-
tion for renal complications 
3, 4. The genetic polymorphisms
of these key components of RAS provide a basis for studying
the relationship between genetic variants and the develop-
ment of vascular and renal damage in patients with DM.
Several polymorphisms were identified in the AGT
gene wich are linked to essential hypertension. Of those,
M235T polymorphism (methionine substituted by threonine)
resulting in M and T alel forms, was extensively studied in
cardiovascular and renal diseases 
4, 5. A TT genotype is asso-
ciated with the progression of limited hypertension into
manifested hypertension as well as with increasing risk for
the diabetic nephropathy level 
6.
Polymorphism of the ACE gene has a frequent inser-
tion-deletion (I/D) polymorphism characterized by the 278-
bp insertion (allele I) or deletion (allele D) variant in intron
16 associated with serum and tissue ACE levels. The I/D
polymorphism, wich determine most of ACE individual vari-
ance was proposed as a genetic marker for DN. The level of
ACE in plasma is in direct correlation with the genotype, and
plays a critical role in determining intrarenal angiotensin and
kinin concentrations 
7.
The AT1R polymorphism located at the position 1166
(A/C) in 3ǯ untranslated region has been considered as a risk
factor for hypertension and cardiovascular disease 
5.
In the present study we examined the distribution of the
AGT, ACE and AT1R gene polymorphisms in patients with
type I DM devided into three groups according to the level of
DN – normoalbuminuric, microalbuminuric or incipient ne-
phropathy and proteinuric or macroangiopathy level. Also,
polymorphisms of three studied genes were correlated with
clinical characteristics of patients with DN.
This study was approved by the Ethic Committee of the
Institute of Diabetes and Metabolic Diseases, Clinical Center
of Serbia, Belgrade.
Methods
All the patients with type 1 DM were presented with
certain criteria and hospitalised in the Institute of Diabetes
and Metabolic Diseases from 2008 to 2010.
The prospective observational study included 79 type 1
diabetic patients, among them 33 had normoalbuminuria, 21
were with microalbuminuria, while 25 patients had protein-
uria. The patients were classified according to the amount of
albuminuria using the median result of the three 24 h urine
collections. Urinary albumin excretion (UAE) was deter-
mined with the nephelometric technique. Normoalbuminuric
level was defined as UAE < 30 mg/24 h, microalbuminuria
as UAE 30–300 mg/24 h and macroalbuminuria or mani-
fested proteinuria as UAE over 300 mg/24 h. Inclusion crite-
ria were age (20–40 years), duration of diabetes (> 5 years)
and the absence of other severe diseases.
Clinical characteristics were gathered from inter-
viewing the patients (duration of diabetes, family history
for hypertension, cardiovascular diseases, diabetes,
smoking duration). The defined risk factors (arterial blood
pressure and complications) were measured on the first
day of visit. Blood samples were drawn for measurement
of serum cholesterol, HbA1c and for the determination of
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Determination of genotypes
Individual genomic DNA samples were extracted from
periferal blood with Applied Biosystems 6100 Nucleic Acid
prep Station instrument.
The AGT (M235T) gene polymorphism and AT1R
(A1166C) gene polymorphisms were analysed by polymer-
ase chain reaction (PCR) and subsequent restriction-
endonuclease digestion (Tth 111I and Hae III) 
8. To deter-
mine the ACE I/D genotype, DNA (100 ng) was amplified
using two insertion-specific primers described by Bon-
nardeaux et al. 
9. The reaction products were visuelised on
2% agarose gel stained with ethidium bromide. Final analy-
sis of the genotype was performed after 10% PAGE stained
with silver nitrate.
Statistical analysis
All statistical analyses were performed in SPSS 12.0
(SPSS Inc, Chicago, Illinois) statistical package). The results
are presented as frequency, percent and mean ± SD. The Ȥ
2,
Kruskal-Wallis and ANOVA test were used to compare the 3
groups, while Mann-Whitney U-test was used to compare the
2 groups. A logistic regression model was performed to asses
associations of nephropathy and other variables. All p-values
that were less than 0.05 were considered significant.
Results
Patient  characteristics (total number 79) are given in
Table 1.
The patients with proteinuria, compared with normo-
and microalbuminuric patients, highly differed in age and
diabetes duration, blood pressure level and hypertension.
There was no statistically significant diference in the
occurence of polyneuropathy among the examined groups of
patients, while the presence of rethinopathy as a frequent mi-
crovascular complication showed high statistically signifi-
cant difference in the group of patients with proteinuria (Ta-
ble 1).
We genotyped all the patients for the AGT, ACE and
AT1R gene polymorphisms. The distribution of genotype
and allele frequencies in the examined groups are presented
in Table 2.
No statistically significant difference among the exam-
ined groups was found in the genotype and allele distribution
for the ACE and AT1R gene polymorphisms.
The carriers of the MT and TT genotype of the AGT
gene polymorphism were more frequent in the group of pa-
tients with elevated UAE. The distribution of homo- and het-
erozygous genotypes for the T allele (MT and TT) was sig-
nificantly higher in the group of patients with proteinuria
when compared to normoalbuminuric patients.
The presence of homozygous TT genotype of the AGT
M235T polymorphism, compared among the 3 devided
groups according to UAE level, was significantly higher in
the group of patients with high albumin excretion.
The genotype and allele distribution for the ACE and
AT1R gene polymorphisms, among the examined groups ac-
cording to elevated albumin excretion, showed no statisti-
cally significant difference.
We found the tendency for statistical significance be-
tween the pressence of TT and I/D gene polymorphisms and
increased blood pressure in patients with proteinuria. The
pressence of MT/TT genotype of AGT M235T gene and
AC/CC genotype of AT1R gene did not reveal a significant
association with retinopathy in the group of patients with
proteinuria, but the homozygous DD genotype of the ACE
gene polymorphism showed an increasing frequency in the
proteinuric group compared with normoalbuminuric patients
(Table 3).
Using the Backward logistic regression model, after
obtaining all predictors associated with renal failure, we
Table 1
Characteristics of diabetes mellitus (DM) patients
Patients characteristics Normoalbuminuria
(n = 33)
Microalbuminuria
(n = 21)
Proteinuria
(n = 25) p-value
Age (years), ʉ ± SD 28.1 ± 5.8 25.8 ± 6.8 34.2 ± 6.8  < 0.001
a
Duration of DM (years), ʉ ± SD 9.6 ± 4.6 11.3 ± 4.4 21.9 ± 5.8  < 0.001
a
Family history of HTA, n (%) 22 (42.3) 14 (26.9) 16 (30.8) ns
c
Family history of DM, n (%) 11 (52.4) 14 (19) 6 (28.6) ns
c
Family history of CVD, n (%) 16 (43.2) 13 (35.1) 8 (21.6) ns
c
Blood pressure (mmHg), ʉ ± SD
systolic 121 ± 12 126 ± 14 148 ± 26 < 0.001
a
diastolic 79 ± 7 85 ± 9 92 ± 15 < 0.001
a
Hypertension, n (%) 9 (24.3) 9 (24.3) 19 (51.4)  < 0.001
c
Polineuropathy, n (%) 13 (30.2) 14 (32.6) 16 (37.2)  ns
c
Retinopathy, n (%) 7 (18.9) 11 (29.7) 19 (51.4)  < 0.001
c
HbA1c (%) 9.3 9.7 10.4 ns
c
Cholesterol, n (%) 11 (39.3) 7 (25.0) 10 (35.7) ns
c
HDL cholesterol (mmol/L), ʉ ± SD 1.25 ± 0.39 1.18 ± 0.44 1.28 ± 0.38 ns
a
LDL cholesterol (mmol/L), ʉ ± SD 3.14 ± 1.06 3.05 ± 1.07 4.00 ± 1.58  ns
b
UAE (mg/24 h) 13.1 ± 5.2 128.1 ± 87.3 368.3 ± 223.8 < 0.001
b
Smokers, n (%) 14 (34.1) 12 (29.3) 15 (36.6) ns
c
HTA – hypertension; CVD – cardiovascular disease; BP – blood pressure; HbA1c – glycohemoglobin A1c; HDL – high density lipoprotein; LDL – low density
lipoprotein; UAE – urinary albumin excretion; n – number of patients in examined groups; ns – not significant; values are calculated by 
aANOVA, 
bKruskal
Wallis; 
c.Ȥ
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Table 2
Distribution of genotypes and allele frequencies of AGT, ACE nad AT1R genes in the examined patients
Genotype Normoalbuminuria
(n = 33)
Microalbuminuria
(n = 21)
Proteinuria
(n = 25) p-value
AGT (M235T), n (%)
M allele
T allele
37 (56)
29 (44)
20 (47.6)
22 (52.4)
19 (38)
31 (62)
ns
a
MM
MT
TT
7 (21.2)
23 (69.7)
3 (9.1)
5 (23.8)
10  (47.6)
6 (28.6)
3 (12.0)
13 (52.0)
9 (36.0)
< 0.05
b
MM+MT
TT
30 (90.1)
3 (9.9)
15 (71.4)
6 (28.6)
16 (64)
9  (36)
< 0.05
c
ACE (I/D), n (%)
I allele
D allele
34 (51.5)
32 (48.5)
25 (59.5)
17 (40.5)
24 (48)
26 (52)
ns
a
II
ID
DD
11 (33.3)
12 (36.4)
10 (30.3)
7 (33.3)
11 (52.4)
3 (14.3)
6 (24.0)
12  (48.0)
7 (28.0)
ns
ab
II+ID
DD
23 (69.7)
10 (30.3)
18 (85.7)
3 (14.3)
18 (72)
7  (28)
ns
c
AT1R (A1166C),  n (%)
A allele
C allele
47 (71)
19 (29)
28 (67)
14 (33)
33 (66)
17 (34)
ns
a
AA
AC
CC
16 (48.5)
15 (45.5)
2 (6.1)
12 (57.1)
4 (19)
5 (22.8)
10 (40.0)
13 (52)
2 (8.0)
ns
b
AA+AC
CC
31 (93.9)
2 (6.1)
16 (76.2)
5 (23.8)
23 (92)
2 (8)
ns
c
aMann-Whitney U test; 
bKruskal-Wallis test; 
cȤ
2 test;
AGT – angiotensinogen; ACE – angiotensin-converting enzyme; AT1R – angiotensin II type I receptor; n – number of patients in examined
groups according to albuminuria (percentages are shown in parentheses); ns – not significant.
Table 3
Genotype distribution according to hypertension, polyneuropathy and rethinopathy
in the examined groups of patients with diabetes mellitus
Genotype distribution Yes, n (%) No, n (%) p-value
Hypertension
AGT
MM 8 (53.3) 7 (46.7) ns
MT/TT 34 (53.1) 30 (46.9) ns
ACE
II 13 (54.2) 11 (45.8) ns
ID/DD 29 (52.7) 26  (47.3) ns
AT1R
AA 20 (52.6) 18 (47.4) ns
AC/CC 22 (53.7) 19 (46.3) ns
Polyneuropathy
AGT
MM 8 (53.3) 7 (46.7) ns
MT/TT 28 (43.8) 36 (56.3) ns
ACE
II 10 (41.7) 14 (58.3) ns
ID/DD 26 (47.3) 29 (52.7) ns
AT1R
AA 16 (42.1) 22 (57.9) ns
AC/CC 20 (48.8) 21 (51.2) ns
Rethynopathy
AGT
MM 5 (33.3) 10 (66.7) ns
MT/TT 37 (57.8) 27 (42.2) ns
ACE
II 14 (58.3) 10 (41.7) ns
ID/DD 28 (50.9) 27 (49.1) ns
AT1R
AA 19 (50.0) 19 (50.0) ns
Ȥ
2 test; AGT – angiotensinogen; ACE – angiotensin-converting enzyme; AT1R – angiotensin II type I receptor;
n – number of patients in examined groups according to albuminuria (percentages are shown in parentheses);
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found that duration of diabetes, high blood pressure, rethi-
nopathy and AGT polymorphism were highly associated
with nephropathy in patients with DM (Table 4).
It was shown that as the duration of diabetes increases
by one unit, the chances of developing nephropathy were
1.192 times higher being statistically significant. If a patient
had hypertension, the likelihood for nephropathy was 5.2
times higher. A patient with TT allele proned to develop ne-
phropathy 28.38 times higher than the carrier of MM geno-
type. If a patient had the MT allele, the chance to develop
nephropathy was 1.358 times greater, but this was not statis-
tically significant. In fact, only the TT genotype showed no-
table importance.
The univariate analyses did not show a statistically sig-
nificant association for ACE/II genotype according to in-
creasing renal complications. The DD genotype in our study
is associated with 0.307 lower risk for nephropathy.
Discussion
We examined the association between the DN level and
genotype distribution of the RAS genes in normoalbuminu-
ric, micro and proteinuric groups of patients with DM type 1.
Also, we analysed main clinical complications in patients
with DM type 1 and correlated them with the studied gene
polymorphisms.
Patients with microalbuminuria are at high risk of car-
diovascular complications and need frequent and careful ex-
amination for early detection of nephropathy, retinopathy,
cardiovascular and lipid abnormalities. Identification of fac-
tors related to the development of microalbuminuria leads to
the development of strategies to prevent nephropathy and re-
duce the occurence of new cases 
8.
Our data suggest a statisticaly significant correlation
between blood pressure level (systolic and diastolic) and re-
thinopathy as more prominent microvascular complication in
patients with terminal renal insuficiency. Both systolic and
diastolic hypertension accelerate the progression of diabetic
nephropathy, and agressive antihypertensive management
successed to decrease the rate of fall of glomerular filtration
rate (GFR) 
10.
In patients with type 1 diabetes, the median life expec-
tancy can significantly increase using appropriate antihyper-
tensive intervention, with the reduction of mortality from
94% to 45%, and the reduction in the need for dialysis and
transplantation from 73 to 31% 16 years after the develop-
ment of overt nephropathy 
11. For patients with nephropathy,
treatment with ACE inhibitors is indicated as a part of initial
therapy concerning previous genotyping analysis of the ACE
gene polymorphism.
In the present study, due to a rather small number of
patients, T allele of the M235T polymorphism and D allel
of the ACE I/D polymorphism tend to be increased in pa-
tients with elevated blood pressure in the proteinuric type 1
diabetes group. Furthermore, current literature suggests that
the ACE D/D genotype predicts poor renal response to
ACE inhibitors and to agents that do not block the RAS in
subjects with DN. Two longitudinal observational studies
pointed out that GFR decreased rapidly in proteinuric type
1 DM patients with the DD genotype 
12, 13.  In the other
study, the albumin excretion rate of type 1 DM patients
with the II genotype increased more rapidly than in those
with the DD genotype, while the response to ACE inhibitor
was better in patients with II than in those with the DD
genotype 
14.
In some follow-up studies, implementation of RAS
blockade therapy in type 1 diabetic patients reduced the pro-
gression to overt DN to 3.4% per year. It should be notified
that 45% of patients in progression of DN decrease microal-
buminuria by intensified antihypertensive treatment 
15.
Several data suggest that hyperglicaemia may be very
important factor for the increasing incidence of cardiovas-
cular complications and progression from microalbuminuric
to DN. Despite previous observational studies findings about
association of poor glycaemic control and progression in al-
buminuria and the rate of progression to DN, we found no
statistically significant correlations in HbA1c values and
quality of glycoregulation between the normoalbuminuric
and microalbuminuric patients. There was no significant in-
creasing serum levels of total cholesterol, low density hipo-
protein (LDL), high density lipoprotein (HDL) cholesterol in
our examined group although it has been reported that dia-
Table 4
Correlation of diabetes mellitus (DM) duration, hypertension (HT), rethinopathy, AGT and ACE gene polymorphism
 with nephropathy in the examined group of patients
Predictor p-value OR (95% CI)
Duration of:
DM < 0.01 1.192 (1.057–1.345)
HT < 0.05 5.200 (1.301–20.790)
rethinopathy < 0.05 2.840 (1.288–6.261)
AGT polymorphism
MM < 0.05 -
MT ns 1.358 (0.234–7.885)
TT < 0.01 28.389 (2.422–332.724)
ACE polymorphism
II ns -
ID ns 2.113 (0.435–10.258)
DD ns 0.307 (0.053–1.780)
AGT – angiotensinogen; ACE – angiotensin-converting enzyme; ns – not significant; OR – odds ratio;
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betic patients could manifest alterations in serum lipid level
ranging from 30 to 90% 
16.
Polymorphisms for different components of RAS have
been described with controversal results according to the dif-
ferent ethnic backgrounds of the study populations, for ex-
ample Asian carriers of 235T allel appear to have a higher
risk of hypertension than white carriers 
17.
On the basis of the previous studies, we cannot con-
clude that there is a link between the ACE I/D polymorphism
and DN. The results differ in a number of studies and data do
not exclude a pathogenic role of mutations somewhere else
in the ACE gene, but prevaling conclusion that the ACE I/D
polymorphism is not a reliable marker for the prediction of
DN in patients with type 1 diabetes 
18. Our data do not indi-
cate an independent effect of ACE and AT1R polymorphism
on the risk for DN, so we are unable to confer the interaction
between the ACE I/D and M235T polymorphism, suggesting
that geneticaly determined AGT levels can cause risk for DN
through Ang I generation.
Previous results in type 1 diabetic patients showed an
association between DN and the T allele of AGT M235T
polymorphism. In the article of Walder et al. 
18, the autors
therefore found that the TT genotype was 3 times more
common in the group of 98 nephropathic than in 98 nor-
moalbuminuric type 1 DM patients, indicating a link to this
genotype and elevated serum angiotensinogen with the pos-
sible risk for DN conferred by this genotype. In the another
study group of hypertensive patients at a start of dialysis,
the carriers of the T allele of the AGT gene were more fre-
quent in the group of patients compared to controls 
6, 19.
The results of our study showed that in patients with hy-
pertension, a likelihood for nephropathy is 5.2 times higher,
while in the group of patients with TT allele risk to develop
nephropathy is 23.38 times higher than in the carriers of
MM genotype.
Our data designate that the T allele occurs more fre-
quently among patients with proteinuria compared with those
with normoalbuminuria, and the level of evidence shows
statistically highly significant difference.
In our study, the T allele of the AGT-M235T polymor-
phism and CC genotype of the AT1-A1166C polymorphism
was not associated with retinopathy.
A recent meta-analysis, including two studies with type
1 diabetic patients, did not find corellation between the AGT
M235T gene polymorphism and diabetic retinopathy. Nev-
ertheless, the associations between RAS activity and reti-
nopathy have been previously reported 
20–23.
Local changes as a result of the presence of different
polimorphisms of RAS are manifested as changes in renal
hemodynamics, increased intraglomerular pressure and glo-
merular filtration rate, as the major determinants of renal
function. The interactions between the alleles of the RAS
probably play a major role in determining the development
of DN. Experimental data might allow identification of
groups with high risk of developing diabetic nephropathy
and, therefore, the analysis of RAS system genes plays an
important role in providing novel therapeutic targets or indi-
vidualized treatment strategies for both the prevention and
treatment of these complications.
Conclusion
The increased association of hypertension and the TT
AGT gene polymorphism in patients with diabetes mellitus
with proteinuria could be a significant marker of diabetic ne-
phropathy.
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